The Percept RC Deep Brain Stimulation (DBS) system (Medtronic, Minneapolis, MN) has been granted approval by the Food and Drug Administration (FDA) as a treatment for movement disorders including Parkinson disease (PD), essential tremor, primary dystonia, as well as for epilepsy. Percept RC DBS is a rechargeable model within the Medtronic Percept line of products, which includes the Percept PC neurostimulator, BrainSense technology, and SenSight.
The Percept RC DBS system is a surgically implanted medical device that delivers electrical stimulation to targeted regions of the brain for therapeutic effect. According to company statements, this is the smallest and thinnest dual-channel DBS device available on the market, and its lower profile enables deeper implantation depths of up to 2 cm. The device is designed with a 15-year service life with greater than 99% battery capacity, and it will allow for future software updates without the need for removal and reimplantation. Percept RC DBS’s battery is capable of recharging from 10% to 90% within an hour. Additionally, the device uses proprietary technology, providing physicians with real-time data collection for patients’ conditions to facilitate adaptable, data-driven treatment personalization.
"This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS," said Amaza Reitmeier, Vice President and General Manager for Medtronic Brain Modulation. "We are excited about the potential of Percept RC to provide a comfortable, personalized DBS therapy to those living with Parkinson’s Disease, Essential Tremor and Primary Dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with Epilepsy.”